Analysis of <i>Epidermal Growth Factor Receptor</i> Gene Mutation in Patients with Non–Small Cell Lung Cancer and Acquired Resistance to Gefitinib
Takayuki Kosaka(Beth Israel Deaconess Medical Center), Tetsuya Mitsudomi(Kindai University), Hideki Endoh(Gunma University), Masahiro Tsuboi(National Cancer Center Hospital East), Kimihide Yoshida(Aichi Cancer Center), Hirohito Tada(Osaka City General Hospital), Toyoaki Hida(Aichi Cancer Center), Yasushi Yatabe(National Cancer Center), Hiroyuki Kuwano(Gunma University)
Cited by 589
Related Papers
International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society International Multidisciplinary Classification of Lung Adenocarcinoma
|Journal of Thoracic Oncology|2011|4.8k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
|Science|2007|4.5k
Reduced Expression of the <b> <i>let-7</i> </b> MicroRNAs in Human Lung Cancers in Association with Shortened Postoperative Survival
|Cancer Research|2004|2.4k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k